Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

the SafeHer Study Group

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients'. Together they form a unique fingerprint.

Medicine & Life Sciences